ID 1910 - Beta-glukany z Saccharomyces cerevisiae

PL: Beta-glukany z Saccharomyces cerevisiae
EN: WGP beta-glucan;(WGP® (1,3)-b-D-glucan);(from Saccharomy-ces cerevisiae)
Pdf: various food(s)/food constituent(s)

1.11. Utrzymanie odporności przeciw patogenom w górnych drogach oddechowych, poprzez utrzymywanie prawidłowego stanu układu odpornościowego (ID 1910)

The claimed effect is “immune system”. The Panel assumes that the target population is the general population.
In the context of the proposed wordings and clarifications provided by Member States, the Panel assumes that the claimed effect refers to the maintenance of the upper respiratory tract defence against pathogens by maintaining immune defences.
The Panel considers that maintenance of the upper respiratory tract defence against pathogens by maintaining immune defences is a beneficial physiological effect.

2.11. Utrzymanie odporności przeciw patogenom w górnych drogach oddechowych, poprzez utrzymywanie prawidłowego stanu układu odpornościowego (ID 1910)

The references provided in relation to this claim included narrative reviews and animal studies which addressed health outcomes (e.g. tumour regression) unrelated to the claimed effect, and a non- scientific reference (web page of a food producer) which did not provide any original data for the
scientific substantiation of the claim. The Panel considers that no conclusions can be drawn from these references for the scientific substantiation of the claim.
No human studies which investigated the effects of the food constituent on maintenance of the upper respiratory tract defence against pathogens by maintaining immune defences were provided in relation to the claim evaluated in this section.
The Panel concludes that a cause and effect relationship has not been established between the consumption of the food constituent which is the subject of the claim evaluated in this section and maintenance of the upper respiratory tract defence against pathogens by maintaining immune defences.

Warunki i możliwe ograniczenia stosowania oświadczenia

250-500 mg per day for adults ;;125 mg per day for children